Gianni, L., Romieu, G., Lichinister, M., Serrano, S., Mansutti, M., Pivot, X., . . . Semiglazov, V. (2013). AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer. American Society of Clinical Oncology.
Chicago Style (17th ed.) CitationGianni, L., et al. AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer. American Society of Clinical Oncology, 2013.
MLA (9th ed.) CitationGianni, L., et al. AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer. American Society of Clinical Oncology, 2013.